Cargando…
HSV-1 Oncolytic Viruses from Bench to Bedside: An Overview of Current Clinical Trials
SIMPLE SUMMARY: Oncolytic Herpes simplex virus-1 (HSV-1) offers the dual potential of both lytic tumor-specific cell killing and inducing anti-tumor immune responses. The HSV-1 genome can be altered to enhance both components and this may be applicable for the treatment of a broad range of cancers....
Autores principales: | Koch, Marilin S., Lawler, Sean E., Chiocca, E. Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760226/ https://www.ncbi.nlm.nih.gov/pubmed/33255871 http://dx.doi.org/10.3390/cancers12123514 |
Ejemplares similares
-
Oncolytic Virotherapy: From Bench to Bedside
por: Yang, Ludi, et al.
Publicado: (2021) -
Bench-to-bedside review: Rhabdomyolysis – an overview for clinicians
por: Huerta-Alardín, Ana L, et al.
Publicado: (2005) -
Expression of HSV-1 Receptors in EBV-Associated Lymphoproliferative Disease Determines Susceptibility to Oncolytic HSV
por: Wang, Pin-Yi, et al.
Publicado: (2012) -
STAT3 Activation Promotes Oncolytic HSV1 Replication in Glioma Cells
por: Okemoto, Kazuo, et al.
Publicado: (2013) -
Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models
por: Koch, Marilin S, et al.
Publicado: (2022)